WASHINGTON – The first human trial to evaluate a candidate vaccine against the new coronavirus has begun in Seattle, US health officials said Monday, raising hopes in the global fight against the disease.
But it may be another year to 18 months before it becomes available, once it has passed more trial phases to prove it works and is safe.
The vaccine is called mRNA-1273 and was developed by US National Institutes of Health (NIH) scientists and collaborators at biotechnology company Moderna, which is based in Cambridge, Massachusetts.
“The open-label trial will enroll 45 healthy adult volunteers ages 18 to 55 years over approximately 6 weeks,” the NIH said. “The first participant received the investigational vaccine today.”
Funding was also provided by the Oslo-based Coalition for Epidemic Preparedness Innovations (CEPI).
There are currently no approved vaccines or treatments against the coronavirus disease, known as COVID-19, which has infected more than 175,000 people across the world since it was first identified in central China in late December.
It has claimed 7,000 deaths, according to an AFP tally, most in China followed by Italy.
“Finding a safe and effective vaccine to prevent infection with SARS-CoV-2 is an urgent public health priority,” said Anthony Fauci, head of infectious diseases at the NIH, using the technical name for the virus that is believed to have originated in bats.
“This Phase 1 study, launched in record speed, is an important first step toward achieving that goal.”
The Seattle trial will study the impact of different doses delivered by intramuscular injection in the upper arm, with participants monitored for side-effects like soreness or fever.
Coronaviruses are spherical and have spikes protruding from their surface, giving them a crown-like appearance. The spike binds to human cells, allowing the virus to gain entry.
The Moderna candidate vaccine carries the genetic information of this spike in a substance called “messenger RNA.”
Injecting human tissue with the spike’s messenger RNA makes it grow inside the body, thereby eliciting an immune response without having actually infected a person with the full-blown virus.
– Global race –
Pharmaceuticals and research labs around the world are racing to develop both treatments and vaccines to the new coronavirus.
An antiviral treatment called remdesivir, made by US-based Gilead Sciences, is already in the final stages of clinical trials in Asia and doctors in China have reported it has proven effective in fighting the disease.
But only randomized trials allow scientists to know for sure whether it really helps or whether patients would have recovered without it. Another US pharma called Inovio, which is creating a DNA-based vaccine, has said it will enter clinical trials next month.
Regeneron is trying to isolate coronavirus-fighting antibodies that can be administered intravenously to confer temporary immunity, and hopes to start human trials by summer.
According to the World Health Organization, 80 percent of COVID-19 cases are mild, 14 percent are severe and about five percent result are critical, resulting in severe respiratory illness that causes the lungs to fill with fluid which in turn prevents oxygen from reaching organs.
Patients with mild cases recover in a week or two while severe cases can take six or more weeks.
Recent estimates suggest about one percent of all infected people die.
China Approves Coronavirus Vaccine For Clinical Trials – State Media
China has authorised clinical trials on its first vaccine developed to combat the new coronavirus, according to a report in the ruling Communist Party’s People’s Daily.
The researchers are led by Chen Wei, of China’s Academy of Military Medical Sciences, it said.
Russia begins testing potential coronavirus vaccine
Russian scientists have begun to test vaccine prototypes for the new coronavirus, and plan to present the most effective one by June, a laboratory chief at a state biotech institute said.
Russia has reported 93 cases of infection but no deaths, according to official numbers published Tuesday.
“The prototypes have been created. We are starting laboratory testing on animals, to ensure effectiveness and safety,” Ilnaz Imatdinov of the Vector Institute in Siberia told the Vesti Novosibirsk television channel on Monday.
“In June we will present one or two showing the best results.”
Vector Institute is a state virology and biotechnology centre in Novosibirsk, which previously worked on vaccines for the Ebola virus.
According to the state health watchdog, which oversees the institute, Russia has tested about 116,000 people for the coronavirus since March 16.
The country has announced it is closing borders to all foreign nationals beginning Wednesday as part of measures to halt the spread of the virus.
Takeda sees speedy approval of coronavirus treatment
Takeda Pharmaceutical Co. said its plasma-derived therapy against coronavirus currently in development has the potential to be among the first approved treatments for the deadly pathogen.
Follow this link to join our WhatsApp group: Join Now
Be Part of Quality Journalism |
Quality journalism takes a lot of time, money and hard work to produce and despite all the hardships we still do it. Our reporters and editors are working overtime in Kashmir and beyond to cover what you care about, break big stories, and expose injustices that can change lives. Today more people are reading Kashmir Observer than ever, but only a handful are paying while advertising revenues are falling fast. |
| ACT NOW |
| MONTHLY | Rs 100 | |
| YEARLY | Rs 1000 | |
| LIFETIME | Rs 10000 | |